@article{d64407f6692f4aaf852a011f2f92fa82,
title = "V122I Transthyretin Cardiomyopathy: An Opportunity to Build Trust and Resolve Disparities",
keywords = "V122I, amyloid cardiomyopathy, tafamidis",
author = "Taimur Sher and Velarde, {Gladys P.} and Gertz, {Morie A.}",
note = "Funding Information: Dr. Sher has served on the Advisory Board and received honoraria from Alnylam Therapeutics; and has received clinical trial support from Akcea Therapeutics. Dr. Gertz has received personal fees from Ionis/Akcea, Alnylam, Prothena, Celgene, Janssen, Annexon, Apellis, Amgen, Medscape, Physicians Education Resource, and Research to Practice; has received grants and personal fees from Spectrum; has received personal fees for the Data Safety Monitoring Board from AbbVie; has received Speakers Bureau fees from Teva, Johnson and Johnson, Medscape, and DAVA oncology; has served on the Advisory Board for Pharmacyclics and Proclara; and has participated in the development of educational materials for i3Health. Dr. Velarde has reported that she has no relationships relevant to the contents of this paper to disclose.",
year = "2020",
month = jul,
day = "7",
doi = "10.1016/j.jacc.2020.04.074",
language = "English (US)",
volume = "76",
pages = "93--95",
journal = "Journal of the American College of Cardiology",
issn = "0735-1097",
publisher = "Elsevier USA",
number = "1",
}